{
    "Trade/Device Name(s)": [
        "Liberty Glucose Normal Control Solution"
    ],
    "Submitter Information": "Liberty Healthcare Group, Inc.",
    "510(k) Number": "K060426",
    "Predicate Device Reference 510(k) Number(s)": [
        "K963500",
        "K052980"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JJX"
    ],
    "Summary Letter Date": "March 9, 2006",
    "Summary Letter Received Date": "February 21, 2006",
    "Submission Date": "February 21, 2006",
    "Regulation Number(s)": [
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [],
    "Specimen Container(s)": [
        "Plastic bottle with dropper-tip"
    ],
    "Instrument(s)/Platform(s)": [
        "Bayer Ascensia DEX 2/DEX Blood Glucose Monitors",
        "BREEZE Blood Glucose Monitors"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for Liberty Glucose Normal Control Solution used as a control material for Bayer Ascensia blood glucose monitoring systems",
    "Indications for Use Summary": "For in vitro diagnostic use by healthcare professionals and home users to assess the performance of Bayer Ascensia DEX 2/DEX and BREEZE Blood Glucose Monitors",
    "fda_folder": "Clinical Chemistry"
}